Availability

Is retatrutide available?

The short answer is no, and the longer answer is about the difference between a clinical trial, an expanded access programme, and a website selling vials.

By Evan Marsh · Updated

There is no approved retatrutide product, so it cannot be prescribed or dispensed. No commercial launch date exists, because a launch would follow an approval and there has been no submission. The routes Lilly describes are its clinical trials and a listed pre-approval expanded access record. Products sold online as “retatrutide” are not FDA-approved Lilly medicines; the FDA has described such products as unapproved new drugs.

There is no prescription route

This is worth stating plainly because a lot of writing about retatrutide implies otherwise. A drug can be prescribed once the FDA has approved it and it has a label. Retatrutide has neither. No physician in the United States can lawfully write a prescription for it as a medicine, no pharmacy can fill one, and no telehealth service can arrange one.

Nor is retatrutide eligible for pharmacy compounding. The FDA's position, set out in its warning letters, is that it does not qualify under either of the compounding exemptions in the Federal Food, Drug, and Cosmetic Act: it is not the subject of a USP monograph, it is not a component of an approved drug, and it is not on the relevant bulk substances lists.

What legitimate access exists

Clinical trials

Lilly's position, on its own site, is that its clinical trials are the route through which people receive retatrutide. Trial participation is not the same as access: eligibility criteria are strict, participants may be randomised to placebo, and most of the Phase 3 programme has stopped recruiting. Recruitment status for every study is recorded onthe trial registry entries listed here, which is the authoritative place to check whether anything is open.

Expanded access

Lilly has registered a pre-approval expanded access record for retatrutide on ClinicalTrials.gov, listed with a status of Available. Expanded access — sometimes called compassionate use — is a regulated pathway through which a patient may receive an investigational drug outside a trial. It requires the sponsor to agree to supply it, a treating physician to request and oversee it, and the FDA to authorise it. It is intended for serious conditions where no comparable alternative exists.

The registry entry isNCT07629401 — Provide Pre-approval Expanded Access of Retatrutide. Whether any individual qualifies is a question for a treating physician and the sponsor, not for a website. This page notes that the pathway is listed; it makes no claim about who can use it.

What is being sold online

Retatrutide is widely offered for sale by websites describing it as a research peptide, usually labelled “for research use only, not for human consumption”. That labelling is not a legal shield, and the FDA has said so directly.

In a warning letter dated 31 March 2026, the FDA told one such seller that the retatrutide products offered on its website are unapproved new drugs under section 201(g)(1) of the Federal Food, Drug, and Cosmetic Act. Several similar letters have gone to other sellers.

What those products contain is not established by anything on this site, and this site does not link to any of them. What can be said is narrower and firmer: they are not the drug Lilly is developing, they have not been reviewed by any regulator, and no one has verified their identity, purity, sterility or dose.

This site carries no links to sellers of research retatrutide, and never will. Directing people searching for approval news toward unregulated injectables is the specific harm this project was built to avoid.

Why there is no launch date

A commercial launch follows approval. Approval follows review. Review follows a filing that the FDA has accepted. As of the last verification, none of those steps has occurred, and the first of them is a plan for Q1 2027.

Even in the most straightforward path — Lilly files on schedule, the FDA accepts the application, the review runs to a standard target date, and the outcome is approval — availability would arrive some time after all of that. Any specific date circulating now is invented.The steps are set out here.

What is known and not known about availability

  • Known: no approved product, no prescription route, no launch date.
  • Known: clinical trials exist, and an expanded access record is listed as Available.
  • Known: the FDA treats retatrutide sold online as an unapproved new drug.
  • Not known: whether the Q1 2027 filing will happen on time.
  • Not known: which indications any approval would cover.
  • Not known: when, or whether, a product would reach pharmacies.

Questions

Is retatrutide available now?

Not as an approved medicine. There is no approved retatrutide product anywhere, so it cannot be prescribed or dispensed by a pharmacy.

When will retatrutide be available?

No availability date exists. Availability would follow FDA approval, and no application has been submitted. Lilly has stated a plan to file in Q1 2027; approval, if it came, would be later still and is not guaranteed.

How can someone legitimately receive retatrutide?

Through participation in one of Lilly’s clinical trials, or potentially through the pre-approval expanded access record Lilly has listed on ClinicalTrials.gov. Expanded access requires the sponsor’s agreement, a treating physician and FDA authorisation. Neither route is a prescription.

Are the retatrutide products sold online real?

They are not FDA-approved Lilly medicines. The FDA has issued warning letters describing retatrutide products offered for sale online, including those labelled research use only, as unapproved new drugs.